- Home
- LIXT vs PALI Comparison
LIXT vs PALI Comparison
Compare LIXT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- PALI
- Stock Information
- Founded
- LIXT 2005
- PALI 1996
- Country
- LIXT United States
- PALI United States
- Employees
- LIXT N/A
- PALI N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LIXT Health Care
- PALI Health Care
- Exchange
- LIXT Nasdaq
- PALI Nasdaq
- Market Cap
- LIXT 4.1M
- PALI 3.5M
- IPO Year
- LIXT N/A
- PALI N/A
- Fundamental
- Price
- LIXT $1.91
- PALI $1.75
- Analyst Decision
- LIXT
- PALI Strong Buy
- Analyst Count
- LIXT 0
- PALI 2
- Target Price
- LIXT N/A
- PALI $23.00
- AVG Volume (30 Days)
- LIXT 33.2K
- PALI 3.7M
- Earning Date
- LIXT 11-12-2024
- PALI 11-12-2024
- Dividend Yield
- LIXT N/A
- PALI N/A
- EPS Growth
- LIXT N/A
- PALI N/A
- EPS
- LIXT N/A
- PALI N/A
- Revenue
- LIXT N/A
- PALI N/A
- Revenue This Year
- LIXT N/A
- PALI N/A
- Revenue Next Year
- LIXT N/A
- PALI N/A
- P/E Ratio
- LIXT N/A
- PALI N/A
- Revenue Growth
- LIXT N/A
- PALI N/A
- 52 Week Low
- LIXT $1.31
- PALI $1.38
- 52 Week High
- LIXT $4.40
- PALI $22.35
- Technical
- Relative Strength Index (RSI)
- LIXT 49.00
- PALI 40.97
- Support Level
- LIXT $1.85
- PALI $1.59
- Resistance Level
- LIXT $2.65
- PALI $2.20
- Average True Range (ATR)
- LIXT 0.20
- PALI 0.39
- MACD
- LIXT 0.01
- PALI 0.02
- Stochastic Oscillator
- LIXT 12.94
- PALI 19.27
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.